Lv1
70 积分 2024-09-01 加入
The hallmarks of cancer immune evasion
22天前
已完结
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
1个月前
已完结
Spatial transcriptomics: a new frontier in accurate localization of breast cancer diagnosis and treatment
1个月前
已完结
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
1个月前
已完结
Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications
1个月前
已完结
Hormone receptor expression in breast cancer: postanalytical issues
1个月前
已完结
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)
1个月前
已完结
Heterogeneity in breast cancer
1个月前
已完结
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
1个月前
已完结
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
1个月前
已完结
皖公网安备34019202002308
